New

Ask Wove anything about tariffs.

Try Tariff Assistant

5'-[3'-(Dimethylamino)propyl]-10',11'-dihydro-5H'-dibenzo[a,d]cyclohepten-5'-ol (Dibenzcarbinol)

Dibenzcarbinol is a complex aromatic amino-alcohol serving as a pharmaceutical intermediate and research chemical. Its structure includes a dibenzocycloheptene core with a dimethylaminopropyl chain and hydroxyl group, explicitly listed under HTS 2922.19.2000 for aromatic amino-alcohols. As a separate chemically defined organic compound, it adheres to Chapter 29's provisions for oxygen-function amino-compounds.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
πŸ‡¨πŸ‡³China5.8%+106.7%112.5%
πŸ‡²πŸ‡½Mexico5.8%+104.2%110%
πŸ‡¨πŸ‡¦Canada5.8%+104.2%110%
πŸ‡©πŸ‡ͺGermanyFree+19.2%19.2%
πŸ‡―πŸ‡΅JapanFree+21.7%21.7%

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

2933.99.97.01Same rate: 112.5%

If containing heterocyclic rings dominating classification

Heterocyclic compounds with nitrogen take precedence in 2933 over amino-alcohols if ring structure is primary feature.

2922.19Same rate: 112.5%

If non-aromatic variant or not specifically named

Other non-aromatic amino-alcohols fall in 2922.19.4000; aromatic specificity limits to .2000 for listed compounds.

2942.00Lower: 16.2% vs 112.5%

If for salts thereof when imported as such

Organic salts not elsewhere specified go to 2942, but Chapter 29 note 3(C) keeps amino-alcohol salts here.

Not sure which classification is right?

The Tariff Assistant works through the GRI rules on your specific product to reach the right HTS code β€” and can price the duty on it in the same conversation.

Import Tips & Compliance

β€’ Provide chemical structure diagrams and CAS number (if available) in import docs to match the precise nomenclature in 2922.19.2000

β€’ Declare as lab or industrial chemical with stabilizer if added for transport, per Chapter 29 note (f), to avoid reclassification

β€’ Watch for pharma-specific FDA regs; improper end-use claims could trigger scrutiny under medicinal headings like 3002